167 related articles for article (PubMed ID: 37879236)
1. Clinical relevance of gene mutations and rearrangements in advanced differentiated thyroid cancer.
Nannini M; Repaci A; Nigro MC; Colapinto A; Vicennati V; Maloberti T; Gruppioni E; Altimari A; Solaroli E; Lodi Rizzini E; Monari F; De Leo A; Damiani S; Pagotto U; Pantaleo MA; de Biase D; Tallini G
ESMO Open; 2023 Dec; 8(6):102039. PubMed ID: 37879236
[TBL] [Abstract][Full Text] [Related]
2. Characterizing Genetic Alterations Related to Radioiodine Avidity in Metastatic Thyroid Cancer.
Mu Z; Zhang X; Sun D; Sun Y; Shi C; Ju G; Kai Z; Huang L; Chen L; Liang J; Lin Y
J Clin Endocrinol Metab; 2024 Apr; 109(5):1231-1240. PubMed ID: 38060243
[TBL] [Abstract][Full Text] [Related]
3. Risk Stratification Using a Novel Genetic Classifier Including
Jung CK; Jung SH; Jeon S; Jeong YM; Kim Y; Lee S; Bae JS; Chung YJ
Thyroid; 2020 Nov; 30(11):1589-1600. PubMed ID: 32326836
[No Abstract] [Full Text] [Related]
4. Risk stratification for radioactive iodine refractoriness using molecular alterations in distant metastatic differentiated thyroid cancer.
Mu Z; Zhang X; Liang D; Fang J; Chen G; Guo W; Sun D; Sun Y; Kai Z; Huang L; Liang J; Lin Y
Chin J Cancer Res; 2024 Feb; 36(1):25-35. PubMed ID: 38455372
[TBL] [Abstract][Full Text] [Related]
5. IGF2 is a potential factor in RAI-refractory differentiated thyroid cancer.
Crezee T; Tesselaar MH; Jaeger M; Rabold K; Corver WE; Morreau H; Van Engen-Van Grunsven ACH; Smit JWA; Netea-Maier RT; Plantinga TS
Oncol Lett; 2021 Aug; 22(2):590. PubMed ID: 34149901
[TBL] [Abstract][Full Text] [Related]
6. Fusion Oncogenes in Patients With Locally Advanced or Distant Metastatic Differentiated Thyroid Cancer.
Ju G; Sun Y; Wang H; Zhang X; Mu Z; Sun D; Huang L; Lin R; Xing T; Cheng W; Liang J; Lin YS
J Clin Endocrinol Metab; 2024 Jan; 109(2):505-515. PubMed ID: 37622214
[TBL] [Abstract][Full Text] [Related]
7. Highly Concordant Key Genetic Alterations in Primary Tumors and Matched Distant Metastases in Differentiated Thyroid Cancer.
Sohn SY; Park WY; Shin HT; Bae JS; Ki CS; Oh YL; Kim SW; Chung JH
Thyroid; 2016 May; 26(5):672-82. PubMed ID: 26971368
[TBL] [Abstract][Full Text] [Related]
8. Predictors of radioiodine (RAI)-avidity restoration for NTRK fusion-positive RAI-resistant metastatic thyroid cancers.
Syed AR; Gorana A; Nohr E; Yuan XK; Amin MASc P; Ghaznavi S; Lamb D; McIntyre J; Eszlinger M; Paschke R
Eur Thyroid J; 2024 Jun; 13(3):. PubMed ID: 38642578
[TBL] [Abstract][Full Text] [Related]
9. Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol.
Iravani A; Solomon B; Pattison DA; Jackson P; Ravi Kumar A; Kong G; Hofman MS; Akhurst T; Hicks RJ
Thyroid; 2019 Nov; 29(11):1634-1645. PubMed ID: 31637953
[No Abstract] [Full Text] [Related]
10. Effect of BRAF
Mu ZZ; Zhang YQ; Sun D; Lu T; Lin YS
Endocr Pract; 2022 Mar; 28(3):265-270. PubMed ID: 34890787
[TBL] [Abstract][Full Text] [Related]
11. Genomic Profiling of Aggressive Thyroid Cancer in Association With its Clinicopathological Characteristics.
Kim JH; Jeong JY; Seo AN; Park NJ; Kim M; Park JY
In Vivo; 2022; 36(1):111-120. PubMed ID: 34972706
[TBL] [Abstract][Full Text] [Related]
12. Impact of 18F-FDG PET/CT on Clinical Management of Suspected Radio-Iodine Refractory Differentiated Thyroid Cancer (RAI-R-DTC).
Lodi Rizzini E; Repaci A; Tabacchi E; Zanoni L; Vicennati V; Cavicchi O; Pagotto U; Morganti AG; Fanti S; Monari F
Diagnostics (Basel); 2021 Aug; 11(8):. PubMed ID: 34441364
[TBL] [Abstract][Full Text] [Related]
13. Relationship between clinicopathologic factors and FDG avidity in radioiodine-negative recurrent or metastatic differentiated thyroid carcinoma.
Ha LN; Iravani A; Nhung NT; Hanh NTM; Hutomo F; Son MH
Cancer Imaging; 2021 Jan; 21(1):8. PubMed ID: 33413689
[TBL] [Abstract][Full Text] [Related]
14. MOLECULAR PROFILE AND CLINICAL OUTCOMES IN DIFFERENTIATED THYROID CANCER PATIENTS PRESENTING WITH BONE METASTASIS.
Malik N; Nikitski AV; Klam E; Hunt J; Witt B; Chadwick B; Nikiforov YE; Abraham D
Endocr Pract; 2019 Dec; 25(12):1255-1262. PubMed ID: 31412230
[No Abstract] [Full Text] [Related]
15. TERT Promoter Mutation Predicts Radioiodine-Refractory Character in Distant Metastatic Differentiated Thyroid Cancer.
Yang X; Li J; Li X; Liang Z; Gao W; Liang J; Cheng S; Lin Y
J Nucl Med; 2017 Feb; 58(2):258-265. PubMed ID: 27493271
[TBL] [Abstract][Full Text] [Related]
16. Case report: Dramatic response to pralsetinib in an elderly patient with advanced RET-fusion positive papillary thyroid carcinoma.
Nannini M; Repaci A; Ricco G; Ianni M; Golemi A; Maiolo V; Ferrari M; Natali F; Rizzini EL; Monari F; Solaroli E; De Leo A; Maloberti T; Pantaleo MA; De Biase D; Tallini G
Front Oncol; 2022; 12():1042525. PubMed ID: 36578928
[TBL] [Abstract][Full Text] [Related]
17. The Genetic Duet of
Liu J; Liu R; Shen X; Zhu G; Li B; Xing M
J Nucl Med; 2020 Feb; 61(2):177-182. PubMed ID: 31375570
[No Abstract] [Full Text] [Related]
18. The genetic duet of BRAF V600E and TERT promoter mutations predicts the poor curative effect of radioiodine therapy in papillary thyroid cancer.
Cao J; Zhu X; Sun Y; Li X; Yun C; Zhang W
Eur J Nucl Med Mol Imaging; 2022 Aug; 49(10):3470-3481. PubMed ID: 35501518
[TBL] [Abstract][Full Text] [Related]
19. Non-Iodine-Avid Disease Is Highly Prevalent in Distant Metastatic Differentiated Thyroid Cancer With Papillary Histology.
Soe MH; Chiang JM; Flavell RR; Khanafshar E; Mendoza L; Kang H; Liu C
J Clin Endocrinol Metab; 2022 Jul; 107(8):e3206-e3216. PubMed ID: 35556126
[TBL] [Abstract][Full Text] [Related]
20. Unique Molecular Signatures Are Associated with Aggressive Histology in Pediatric Differentiated Thyroid Cancer.
Mollen KP; Shaffer AD; Yip L; Monaco SE; Huyett P; Viswanathan P; Witchel SF; Duvvuri U; Simons JP
Thyroid; 2022 Mar; 32(3):236-244. PubMed ID: 34915753
[No Abstract] [Full Text] [Related]
[Next] [New Search]
